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With severe disease manifestations including microcephaly, congenital malformation, and Guillain–Barré syndrome, Zika virus 
(ZIKV) remains a persistent global public health threat. Despite antigenic similarities with dengue viruses, structural studies have 
suggested the extended CD-loop and hydrogen-bonding interaction network within the ZIKV envelope protein contribute to sta-
bility differences between the viral families. This enhanced stability may lead to the augmented infection, disease manifestation, and 
persistence in body fluids seen following ZIKV infection. To examine the role of these motifs in infection, we generated a series of 
ZIKV recombinant viruses that disrupted the hydrogen-bonding network (350A, 351A, and 350A/351A) or the CD-loop extension 
(Δ346). Our results demonstrate a key role for the ZIKV extended CD-loop in cell-type-dependent replication, virion stability, and 
in vivo pathogenesis. Importantly, the Δ346 mutant maintains similar antigenicity to wild-type virus, opening the possibility for its 
use as a live-attenuated vaccine platform for ZIKV and other clinically relevant flaviviruses.
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Zika virus (ZIKV) is a flavivirus with a single-stranded posi-
tive-sense RNA genome of approximately 11 kb [1]. ZIKV is 
transmitted by Aedes aegypti and Ae. albopictus mosquitoes. 
It was first isolated in Uganda in 1947 [2] and caused spo-
radic outbreaks, mainly in Africa, Asia, and the South Pacific 
[3]. ZIKV has recently emerged as a global health threat after 
introduction to Brazil in 2015 and subsequent spread through 
South and Central America [4]. While ZIKV causes disease 
similar to related flaviviruses, infection is also associated with 
neurological pathologies like Guillain–Barré syndrome and 
meningoencephalitis [5], as well as fetal abnormalities such as 
microcephaly, placental insufficiency, and fetal demise [6, 7]. 
ZIKV has also been detected in fluids and tissues (tears, semen, 
testes, etc.) atypical of other flaviviruses, suggesting a unique 
pathobiology not common to other highly related viruses [8].
Like other flaviviruses, the surface of ZIKV is composed of 
the envelope protein (E), which is divided into three domains, 
domain I (EDI), II (EDII), and III (EDIII) [9]. Multiple 
cryo-electron microscopy (cryoEM) crystal structures found 
that the overall ZIKV structure is similar to dengue virus 
(DENV) and West Nile virus [9, 10], with subtle differences. 
The ZIKV E protein contains additional residues surround-
ing a glycosylation site in EDI, which might be important for 
attachment to host cells [9]. Additionally, the CD-loop in EDIII 
contains one additional amino acid relative to some other flavi-
viruses, allowing the loop to reach further into the 5-fold vertex 
(Figure 1A) [10]. This extended loop is predicted to augment 
ZIKV stability by facilitating a hydrogen-bond network among 
the five E monomers via a glutamine at position 350 of one 
molecule and a threonine at position 351 of the neighboring E 
molecule (Figure 1A) [10]. Multiple groups have since shown 
that mutating residue 350 and/or 351 has little to no impact on 
virus thermostability [11, 12]. These data suggest it is not the 
hydrogen-bonding within the CD-loop that leads to increased 
stability.
The extended CD-loop provides an alternative means of 
enhanced ZIKV stability, which is supported by reports that 
deletion of the CD-loop extension resulted in nonviable virus 
[12]. In this study, we used a H/PF/2013 ZIKV infectious clone 
[13] to generate a panel of viral mutants around the CD-loop.
All viruses, including a residue 346 deletion (Δ346), were recov-
ered and grew to high titer in multiple cell types. Consistent
with prior reports, viruses with mutations designed to disrupt
hydrogen-bonding (350A, 351A, and 350A/351A) showed no
in vitro attenuation or decrease in thermostability. However,
shortening the CD-loop by one amino acid attenuated the
virus yields and led to a decrease in virus stability. Consonant
with thermostability results, cryoEM analyses revealed that the
deletion mutation (Δ346) destabilizes the virion, even at room
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temperature. Importantly, all CD-loop mutant viruses main-
tained general ZIKV morphology and functional neutralizing 
antibody epitopes. In addition, the deletion mutant is attenuated 
in a mouse model of ZIKV disease. Overall, our data suggest 
that small changes in the ZIKV envelope improve stability and 
may play an important role in viral disease and pathogenesis.
METHODS
Viruses and Cells
Viruses were generated using our ZIKV H/PF/2013 reverse 
genetics infectious clone system [13]. Briefly, the viral genome 
was divided into four plasmids with unique type II restriction 
endonuclease sites at each end of the fragment. Fragments were 
digested, ligated together, in vitro transcribed, and electropo-
rated into C6/36 cells. After incubating 4–6 days, cell culture 
supernatant was harvested, filtered to remove cellular debris, 
and passaged once on C6/36 cells to make a working stock.
To generate CD-loop mutant viruses, the following primers 
were used and polymerase chain reaction (PCR) was performed 
to introduce the mutations. Primer sequences listed 5′–3′ were: 
Δ346 forward (GTCAGAGTTTGCATGTCCACCATCTGAGC 
TGGAACCTTGC), Δ346 reverse (GTGGACATGCAAAC 
TCTGACC); 350A forward (ACTCTGACCCCAGTTGGGAG), 
350A reverse (CTCCCAACTGGGGTCAGAGTTGCCATGT 
CCACCGCCATCTGAG); 351A forward (CTGACCCCAGTT 
GGGAGGTTG), 351A reverse (CAACCTCCCAACTGGGG 
TCAGAGCTTGCATGTCCACCGCCATCTGAG); and 350A/ 
351A forward (ACTCTGACCCCAGTTGGGAG), 350A/ 
351A reverse (CAACCTCCCAACTGGGGTCAGAGCTG 
CCATGTCCACCGCCATCTGAG). New plasmids containing 
CD-loop mutations were then digested and ligated as described
above to make recombinant virus.
C6/36 cells (ATCC® CRL-1660) were maintained in Minimum 
Essential Medium, supplemented with 5% fetal bovine serum, 
1% nonessential amino acids, and 1% antibiotic-antimycotic. 
Vero cells (ATCC® CCL-81) were maintained in Dulbecco’s 
Modified Eagle Medium with 5% fetal bovine serum, and 1% 
antibiotic–antimycotic. Cells were cultured in 5% CO2 at 37°C 
(Vero) or temperature-adapted to 32°C (C6/36).
Titering and Immunostaining
Viruses were serially diluted and added to approximately 80% 
confluent C6/36 or Vero cells. Diluted viruses were incubated 
on cells for 1 hour at 32°C (C6/36) or 37°C (Vero), then overlaid 









Figure 1. Zika virus (ZIKV) CD-loop and mutant virus design. A, The CD-loop of ZIKV contains a glutamine at position 350 and a threonine at position 351 and these resi-
dues are predicted to form a network of hydrogen bonds between the E proteins near the 5-fold vertex (Protein Data Bank = 5IZ7) [10]. B, Side view of CD-loop from a single 
envelope monomer. Residues 346, 350, and 351 that were altered in the CD-loop ZIKV mutant viruses are highlighted in green, magenta, and orange, respectively. C, Amino 
acid alignment of CD-loop region of ZIKV and related flaviviruses. Amino acid changes in mutant viruses are highlighted in red.
fixed with 50% methanol + 50% acetone and either stained with 
0.25% crystal violet or immunostained with anti-E monoclonal 
antibody (MAb) 4G2.
Droplet Digital PCR
RNA was isolated from virus stocks using QIAGEN Viral 
RNA Isolation kit. Viral RNA was reverse-transcribed 
using Bio-Rad One-Step RT-ddPCR Kit for Probes and 
ddPCR Supermix, using the following primers and probe, 
listed 5′–3′: forward (GGATATTCAGGAACCCTGGC) 
reverse (AGTCCCACCTGACATACCTT), probe 
(GCAGCAGCTGCCATCGCTTGGCT) [14]. Droplets were 
generated and absolute genome copy numbers were determined 
using Bio-Rad QX200 Droplet Digital PCR System [15].
Growth Curves
C6/36 or Vero cells were infected in triplicate at a multiplicity of 
infection (MOI) of either 0.01 or 1, for 1 hour at 32°C (C6/36) 
or 37°C (Vero). After incubation, wells were washed with PBS 
to remove unbound virus, and fresh growth media was added 
to wells. Every 6–24 hours, culture supernatant was removed, 
immediately frozen at −80°C, then titered as described above. 
Cells were washed, fixed in 10% formalin, permeabilized, and 
stained with anti-E MAb 4G2 conjugated to AlexaFluor 488. 
Infected cells were quantified using flow cytometery (Guava® 
easyCyte, Millipore).
Temperature Stability Assay
For temperature-dependent stability assay, virus stocks were 
diluted 1:10 and incubated at either 4°C, 28°C, 37°C, or 40°C for 
8 hours. Viruses were immediately titered as described above. 
For temperature time course assay, viruses were diluted 1:10 
and incubated at 37°C. Samples were removed at various time 
points, immediately frozen at −80°C, and subsequently titered 
together as described above. Relative infectivity was determined 
as (focus forming units [FFU]/mLtest temperature/FFU/mL4°C) × 
100 for temperature-dependent assay, and (FFU/mLtime indicated/
FFU/mLt=0h) × 100 for time-dependent assay.
Cryo-Electron Microscopy
Viruses were prepared as previously described [10, 16]. Briefly, 
viruses were grown in C6/36 cells, precipitated in polyeth-
ylene glycol, pelleted by ultracentrifugation, purified through a 
sucrose cushion, then purified in a potassium tartrate gradient. 
Virus samples were incubated at 4°C, 29°C, 37°C, or 40°C for 
30 minutes then frozen onto copper cryoEM grids. Micrograph 
images were collected on a Titan Krios (FEI) microscope.
Binding Enzyme Linked Immunosorbent Assay
Ninety-six well plates were coated with mouse anti-E MAb 4G2 
overnight at 4°C. Plates were blocked with 3% nonfat dried 
milk, and viruses were captured. Primary human MAb C10 was 
diluted and added to wells, then goat-α-human-IgG alkaline 
phosphatase (AP) labeled secondary antibody was added. Plates 
were developed with p-nitrophenyl phosphate substrate, and 
color changes were quantified by spectrophotometry.
Monoclonal Antibody Focus Reduction Neutralization Test
Human MAb C10 was diluted 4-fold starting at 10ng/μL and 
mixed with approximately 50 FFU of virus, and MAb:virus mix-
ture was incubated at 32°C for 1 hour. MAb:virus mixture was 
added to approximately 80% confluent C6/36 cells and incu-
bated an additional hour at 32°C. After incubation, 1% methyl-
cellulose overlay was added to cells, and plates were incubated 
4 days. Cells were fixed and stained as described above.
Mouse Infections
Male and female 11-week-old type I and type II interferon 
receptor knockout mice (IFNAR−/− IFNGR−/−) on C57BL/6 
background were provided from Jason Whitmire at University 
of North Carolina, and were infected with 103 C6/36 FFU in 
10μL via a footpad injection. Survival and weight loss were 
monitored daily across a 28-day period. At day 6 post-infection, 
a subset of mice were euthanized, sera and brains were collected 
and immediately stored at −80°C. Sera and brain homogenates 
were titered as described. Animals were humanely euthanized 
upon dropping below 80% of their starting weight or showed 
signs of disease. All animal work was performed in adherence 
to the Institutional Animal Care and Use Committee (IACUC) 
and University of North Carolina at Chapel Hill policy.
RESULTS
Design of Zika Virus CD-Loop Mutants
To investigate the role of ZIKV’s extended CD-loop and poten-
tial inter-envelope hydrogen-bonding, we designed a panel of 
CD-loop mutants using a ZIKV H/PF/2013 infectious clone
(Figure 1) [13]. Relative to DENV, but similar to other flavivi-
ruses (Figure 1C), ZIKV contains an additional amino acid in
the CD-loop at position 346, allowing the loop to reach farther
into the 5-fold vertex (Figure 1A and B) [10]. To determine the
impact of the extended loop, we generated a recombinant virus
(Δ346) removing the alanine at position 346 (Figure 1C). To
study the impact of inter-envelope hydrogen-bonding between
glutamine at position 350 and threonine at position 351 across
neighboring molecules (Figure 1B), we individually or together
mutated these resides to alanine to disrupt these interactions
(350A, 351A, and 350A/351A, respectively) (Figure 1C).
CD-loop mutants were generated using an infectious clone and
recovered in C6/36 cells.
Characterizing CD-Loop Mutants
Viral stocks grown on C6/36 cells indicated roughly equivalent 
levels of genome copies, suggesting similar virus-packaging of 
genomes (Supplementary Figure 1A). When titered on C6/36 
cells, 350A, 351A, and 350A/351A mutant titers were similar 
to WT ZIKV, whereas Δ346 was approximately 1 log attenu-
ated (Figure 2A). Titering the same stocks on Vero cells showed 
a similar pattern, where 350A, 351A, and 350A/351A mutant 
titers were similar to WT ZIKV; however, Δ346 was attenu-
ated by 2 logs (Figure 2B). This difference was also highlighted 
in a higher genome to FFU ratio for the Δ346 mutant in Vero 
cells (Supplementary Figure  1B). Additionally, the ratio of 
Vero titer to C6/36 titer showed that WT ZIKV, 350A, 351A, 
and 350A/351A had 1/10th the infectious virus on Vero cells 
relative to C6/36 cells, whereas Δ346 had 1/100th the amount 
(Supplementary Figure 1C). To determine whether this differ-
ence in ratio in the Δ346 mutant is cell-type dependent or due to 
different culture temperatures of C6/36 and Vero cells (32°C or 
37°C, respectively), we titered viruses on Vero cells at both tem-
peratures. Independent of incubation temperature, WT ZIKV, 
and Δ346 titers did not change (Supplementary Figure  1D), 
suggesting cell-type dependent attenuation of mutant Δ346.
While CD-loop mutants make viral foci similar to those of 
WT ZIKV in C6/36 cells, Δ346 foci were substantially smaller 
than those of WT ZIKV in Vero cells (Figure 2C), in contrast to 
the 350A, 351A, and 350A/351A mutants. Additionally, Δ346 
did not plaque in Vero cells after the standard 4 days of incu-
bation, requiring additional time (5–7 days) to generate small 
plaques (Supplementary Figure 2). These data suggest that Δ346 
mutant is attenuated in cell-to-cell spread in Vero cells, whereas 
the other mutants show no attenuation.
CD-Loop Mutant Replication
To extend our analysis of mutant virus growth, we performed 
growth curves to evaluate replication attenuation. In a multistep 
growth curve (MOI = 0.01) on C6/36 cells, Δ346 was slightly 
attenuated relative to WT ZIKV and reached significantly lower 
peak titer (Figure 3A), despite similar levels of infected cells 
(Supplementary Figure 3A). At a higher MOI of 1, all viruses 
had similar replication kinetics; however, Δ346 still reached a 
significantly lower peak titer (Figure 3A, Supplementary Figure 
3A). More robust attenuation of Δ346 was observed in Vero 
cells at early times in both low and high MOIs (P < .01); how-
ever, the Δ346 mutant eventually reached a similar peak titer 
(Figure 3B). Interestingly, the Q350A and T351A single and 
double mutants appeared to be enhanced in growth relative to 
WT virus in multicycle growth curves in both cell types (Figure 
3A and B). Disrupting CD-loop hydrogen-bonding interactions 
potentially improves virus entry, fusion, assembly, or egress, 
leading to an improved growth of these viruses. Together, the 
peak titer and multistep growth curve data indicate a critical 
early role for the extended CD-loop in ZIKV replication and 




































































Figure 2. Recovery of infectious CD-loop mutants. A,B, The focus forming units (FFU) (mean ± standard deviation) of the virus stocks were determined on (A) C6/36 and (B) 
Vero cells. C, Viruses were titered on C6/36 or Vero cells and immunostained with anti-E MAb 4G2, or crystal violet. WT, wild type.
Δ346 Mutation Disrupts Virus Temperature Stability
To explore if changes in virus stability reduced viral replication, 
the mutant viruses were incubated at a range of temperatures 
and subsequently titered on C6/36 cells. For all viruses, sim-
ilar stability was observed at both 4°C and 28°C (Figure 3C). 
However, the Δ346 mutant had significantly reduced infectiv-
ity (P < .05) at both 37°C and 40°C relative to WT ZIKV as 
well as the 350A, 351A, and 350A/351A mutants (Figure 3C). 
Extending this analysis, we examined intrinsic decays of each 
virus at the physiologically relevant temperature 37°C, and sam-
pled over the course of 48 hours. While WT ZIKV, 350A, 351A, 
and 350A/351A all decayed at similar rates, the Δ346 mutant 
lost infectivity significantly (P < .01) faster at this temperature 
(Figure 3D). Together, the data argue that reduced temperature 
stability might contribute to the attenuation of the Δ346 mutant.
Shortening the CD-Loop Destabilizes Virus
The CD-loop mutants were designed to disrupt inter-envelope 
interactions at the 5-fold vertex on the intact virion, by either 
shortening the CD-loop (Δ346) or disrupting hydrogen bond 
interactions (350A, 351A, and 350A/351A). The temperature sta-
bility results suggest that the extended CD-loop rather than the 
hydrogen bond interactions are critical for ZIKV thermostability 
(Figure 3C and D). To determine if the Δ346 mutant has reduced 
overall stability, cryoEM was performed on the Δ346 and other 
CD-loop mutants. CyroEM micrographs indicate that WT ZIKV is 
structurally stable even up to 40°C, maintaining primarily spherical 
virion morphology (Figure 4), consistent with previous work [10]. 
Interestingly, even at 4°C, the Δ346 mutant is highly unstable with 
only a small fraction of particles appearing spherical (Figure 4). 
Increasing the incubation temperature of the viruses after cryoEM 
virus purification did not appear to increase the instability of the 
virus or the fraction of broken particles. It is possible that the Δ346 
is breaking apart during the virus preparation and ultracentrifuga-
tions for cryoEM, and therefore any additional manipulations after 
this preparation did not further impact stability. Consistent with 
growth and temperature stability results (Figure 3), 350A, 351A, 
and 350A/351A mutants looked similar to WT ZIKV (Figure 4), 
with temperature having little impact. These results suggest that 
modification of the ZIKV CD-loop reduces the stability of the 
virion and may impact viral replication and propagation.
Mutant Viruses Maintain Zika Virus Morphology and Neutralizing 
Antibody Epitopes
While alteration of E protein residues has produced viable 
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Figure 3. Δ346 mutant is attenuated in growth and thermally unstable. Growth curves of wild type (WT) and mutant viruses in (A) C6/36 cells or (B) Vero cells. C, Thermal 
stability of viruses that were incubated at 4°C, 28°C, 37°C, or 40°C for 8 hours, and then titered on C6/36 cells. Relative infectivity was calculated as (focus forming units 
[FFU]/mLtest temperature/FFU/mL4°C) × 100 (mean ± standard error of the mean [SEM]). D, Infectivity of viruses when incubated for various timings at 37°C. Relative infectivity 
was calculated as (FFU/mLtime indicated/FFU/mLt=0h) × 100 (mean ± SEM). One-way analysis of variance followed by Dunnett’s multiple comparisons test was conducted on 
log-transformed data (*P < .05). Dotted lines represent limit of detection.
result in disrupted ZIKV virion morphology, antigenic presen-
tation, and contribute to reduced thermostability. To ensure 
conservation of important ZIKV neutralizing epitopes, we 
evaluated each mutant for the ability to bind C10, an enve-
lope dimer epitope (EDE) cross-reactive DENV antibody [16, 
20, 21]. Each CD-loop mutant bound C10 with similar kinet-
ics to WT ZIKV (Figure 5A). Importantly, the epitope was not 
only maintained in mutant viruses, but also retained the abil-
ity to be neutralized by C10 with similar neutralization titers 
(Figure  5B). Importantly, infectious virus produced by cells 
used in binding and neutralization assays, maintained this 
functional epitope, corroborating that the structural instability 
of Δ346 seen in cryoEM micrographs is instead likely due to 
the strenuous preparation process for cyroEM analyses, includ-
ing multiple ultracentrifugations. Overall, these results suggest 
that despite modification of the CD-loop, ZIKV antigenicity 
remained intact.
Δ346 is Attenuated in a Mouse Model of Zika Virus Pathogenesis
To determine the impact of thermoinstability of the Δ346 mutant 
on in vivo pathogenesis, we utilized a mouse model of ZIKV infec-
tion and pathogenesis [22]. Using 11-week-old type I and type II 
interferon receptor knockout mice, we infected with 103 FFU WT 
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Figure 5. CD-loop mutants maintain Zika virus antigenicity. A, Enzyme-linked-immunosorbent-assay and (B) focus reduction neutralization test (FRNT) was performed with 
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Figure 4. Deletion mutation at the ZIKV CD-loop leads to structural instability. CryoEM micrographs of wild type (WT) and CD-loop mutant virus particles after incubation 
at 4°C, 29°C, 37°C, and 40°C for 30 minutes. Scale bar is 50 nm.
All mice infected with WT ZIKV succumbed to disease by day 
16 (Figure  6A), with weight loss beginning day 7 postinfection 
(Figure 6B). Conversely, infection with Δ346 resulted in no signif-
icant disease or weight loss (Figure 6A and B). To confirm produc-
tive infection of each virus, serum virus titer was measured at day 
6. Surprisingly, mice infected with either WT ZIKV or the Δ346
mutant had comparable serum viremia (Figure 6C). At the same
time-point however, fewer mice infected with Δ346 had detectable 
virus in their brain, and those with virus had lower titer virus than 
those infected with WT ZIKV (Figure 6C). These results suggest
that attenuation of the Δ346 mutant in mice is not primarily due to 
lack of replicating virus early during infection, but might be due to 
trafficking to, or replication in, the brain.
DISCUSSION
In this study, we examined the role of ZIKV’s extended CD-loop 
and potential hydrogen-bonding interactions on virus stability 
using a series of structurally designed mutants. Despite initial 
predictions [10], disrupting the hydrogen  bond interactions 
through three different mutations (350A, 351A, and 350A/351A) 
had little to no impact on virus titer, replication, stability, or 
structural morphology. Combined with previous reports, these 
results show that the predicted hydrogen-bonding across enve-
lope proteins at the 5-fold vertex is not primarily responsible 
for ZIKV’s thermostability [11, 12]. In contrast, removing a sin-
gle residue from the ZIKV CD-loop led to a decrease in virus 
titer, foci size, ability to plaque in Vero cells, and thermosta-
bility. While a previous study argued the extended CD-loop 
is essential for ZIKV assembly as they were unable to recover 
virus from electroporated Vero cells [12], electroporation into 
the more permissive C6/36 cells allowed recovery of the Δ346 
mutant, suggesting cell-type-dependent viability or differences 
in the efficiencies of recovering debilitated mutants in the two 
molecular clone systems. Additionally, the Δ346 mutant was 
attenuated in a mouse model of ZIKV disease, with lower titer 
in the brain and decreased pathogenesis. Importantly, while 
shortening the CD-loop maintained general ZIKV morphol-
ogy and neutralizing antibody epitopes, it also disrupted virion 
structural stability, consistent with temperature stability results. 
It is possible that maturation state and or differences in sensi-
tivity to pH changes might also impact mutant virus stability. 
Together, the results confirm a significant role for the extended 
CD-loop in ZIKV infection and pathogenesis.
These results illustrate the utility of mechanistic validation of
structural predictions. While initial analyses indicated a role for 
hydrogen-bonding in the ZIKV CD-loop leading to enhanced 
stability, these and other studies have now shown that preventing 
these hydrogen-bonding interactions has little impact on stabil-
ity [11, 12]. In contrast, our data provide direct evidence that the 
CD-loop extension is at least partially responsible for enhanced
stability. Notably, ZIKV has been detected in fluids and tissues
(tears, semen, testes, etc.) not seen with the related DENV strains, 
which maintain a shorter CD-loop [8]. One possibility is that
ZIKV’s extended CD-loop provides a thermo- and structural sta-
bility advantage that permits persistence, travel to organs and flu-
ids atypical of the related DENVs [23]. Importantly, conservation 
of the extended CD-loop in other flaviviruses, including West
Nile and yellow fever viruses (YFV), may signal this modification 
as a possible correlate for pathogenesis; mutation of these loops
in other flaviviruses may render similar attenuation as seen with
the Δ346 mutant. While the YFV vaccine was heavily passaged to 
attenuate the virus, the mechanism of attenuation is still poorly
understood and vaccination occasionally results in adverse side
effects, especially in the elderly [24–28]. While speculative, it is
possible shortening the CD-loop of the YFV vaccine may further 
attenuate the virus and lead to better tolerability.
In addition to loss of virion stability and in vitro attenua-


































































Figure 6. Δ346 mutant is attenuated in a mouse model of Zika virus disease. A–C, Eleven-week old type I/II interferon receptor knockout mice were infected with 103 C6/36 
focus forming units via footpad injection and monitored for (A) survival (log-rank test, *P < .05) and (B) weight loss (mean ± standard error of the mean [SEM]) (two-tailed 
Student t test, *P < .05). C, Mice were harvested at day 6, and serum and brain were collected and titered on C6/36 cells (mean ± SEM). Virus below limits of detection are 
plotted on x axis. WT, wild type.
Infection with the CD-loop mutant produced minimal weight 
loss, the absence of lethality, and diminished brain titers in 
type I/II IFN receptor knockout mice. Importantly, despite the 
structural instability, the CD-loop mutant maintains similar 
antigenicity to WT ZIKV based on antibody binding and neu-
tralization by the envelope-dimer epitope antibody. With future 
availability of additional ZIKV-specific monoclonal antibodies, 
more thorough analysis can be performed to evaluate CD-loop 
mutant virus morphology, presentation of epitopes, and anti-
genicity. These results indicate that the Δ346 mutation could 
serve as a backbone for a live attenuated vaccine platform [29]. 
However, further studies, including examination of persistence 
in peripheral tissues, antibody/protection responses, possibil-
ity for reversion, and potential mosquito transmission, are still 
required. Notably, based on conservation across other flavivi-
ruses, manipulation of the CD-loop extension may have impli-
cation beyond ZIKV for vaccine design.
In the context of an outbreak, varying research approaches 
must work in concert to develop both understanding and 
therapeutic interventions. While epidemiological studies pro-
vide critical insights, they are inherently limited by the qual-
ity of reporting and surveillance in the epidemic setting [30]. 
Similarly, rapid publication of ZIKV cryoEM structures [9, 
10] allowed predictions of factors that influence the emerging
infection, but could not test those observations. In this study, we 
have leveraged a newly developed ZIKV infectious clone [13]
to explore and test insights from structure based studies. The
resulting rationally designed mutants confirmed the impor-
tance of the CD-loop extension, but not hydrogen-bonding,
in ZIKV stability. Importantly, the approach to integrate these
diverse strategies can be applied to newly emerging viruses to
elucidate mechanisms of pathogenesis and design next-gener-
ation therapeutics.
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